Navigating Uncharted Territory in Surgical Innovation: A systematic review of non-standard Metabolic Bariatric Surgery procedures.

IF 8.8 1区 医学 Q1 SURGERY
Francesco Saverio Papadia,Ottavio De Cian,Nicola Di Lorenzo,Ricardo Vitor Cohen
{"title":"Navigating Uncharted Territory in Surgical Innovation: A systematic review of non-standard Metabolic Bariatric Surgery procedures.","authors":"Francesco Saverio Papadia,Ottavio De Cian,Nicola Di Lorenzo,Ricardo Vitor Cohen","doi":"10.1093/bjs/znag047","DOIUrl":null,"url":null,"abstract":"BACKGROUND\r\nSurgical innovation often outpaces robust evaluation. This study used metabolic bariatric surgery (MBS), a field of high-intensity innovation, as a case study to evaluate reporting standards and ethical oversight for experimental procedures within surgery.\r\n\r\nMETHODS\r\nWe conducted a systematic review in accordance with PRISMA 2020 guidelines. We searched PubMed/MEDLINE, Web of Science, Scopus, Cochrane Library, and Embase from January 2000 to December 2024 using terms related to metabolic bariatric surgery, surgical innovation, and non-standard intestinal bypass procedures. We included original studies reporting first-in-human or early clinical series of non-standard primary MBS involving significant intestinal modification, and excluded reviews, editorials, conference abstracts, revisional surgery, purely restrictive procedures, and device-based interventions. Two reviewers independently screened studies, extracted data on publication timing, patient numbers, follow-up, ethical approval, and trial registration, and assessed risk of bias using the Newcastle-Ottawa Scale, Joanna Briggs Institute checklist, and ROBINS-I tool.\r\n\r\nRESULTS\r\nFrom 57 included studies (10,754 patients), the median time from first human operation to publication was 5 years (IQR 3-8 years). The median initial cohort size was 39 patients (range 1-1074 patients). Institutional review board or ethical approval was reported in 47/57 studies (82%), while prospective clinical trial registration was documented in only 6/57 studies (11%). Methodological quality was low (mean Newcastle-Ottawa Scale score 5.0/9), with 56 of 57 studies judged at high risk of bias. Out of 57, studies, only 15 (26%) reported outcomes at ≥3 years, and 8 studies (14%) at ≥5 years.\r\n\r\nCONCLUSION\r\nThis MBS case study reveals delayed publication and a widespread lack of prospective trial registration, exposing over 10,000 patients to experimental procedures outside a transparent research framework. These findings highlight a systemic failure in surgical innovation governance and underscore an urgent need for a cultural shift towards mandatory, prospective oversight frameworks to ensure patient safety and credible evidence generation.","PeriodicalId":136,"journal":{"name":"British Journal of Surgery","volume":"13 1","pages":""},"PeriodicalIF":8.8000,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/bjs/znag047","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

BACKGROUND Surgical innovation often outpaces robust evaluation. This study used metabolic bariatric surgery (MBS), a field of high-intensity innovation, as a case study to evaluate reporting standards and ethical oversight for experimental procedures within surgery. METHODS We conducted a systematic review in accordance with PRISMA 2020 guidelines. We searched PubMed/MEDLINE, Web of Science, Scopus, Cochrane Library, and Embase from January 2000 to December 2024 using terms related to metabolic bariatric surgery, surgical innovation, and non-standard intestinal bypass procedures. We included original studies reporting first-in-human or early clinical series of non-standard primary MBS involving significant intestinal modification, and excluded reviews, editorials, conference abstracts, revisional surgery, purely restrictive procedures, and device-based interventions. Two reviewers independently screened studies, extracted data on publication timing, patient numbers, follow-up, ethical approval, and trial registration, and assessed risk of bias using the Newcastle-Ottawa Scale, Joanna Briggs Institute checklist, and ROBINS-I tool. RESULTS From 57 included studies (10,754 patients), the median time from first human operation to publication was 5 years (IQR 3-8 years). The median initial cohort size was 39 patients (range 1-1074 patients). Institutional review board or ethical approval was reported in 47/57 studies (82%), while prospective clinical trial registration was documented in only 6/57 studies (11%). Methodological quality was low (mean Newcastle-Ottawa Scale score 5.0/9), with 56 of 57 studies judged at high risk of bias. Out of 57, studies, only 15 (26%) reported outcomes at ≥3 years, and 8 studies (14%) at ≥5 years. CONCLUSION This MBS case study reveals delayed publication and a widespread lack of prospective trial registration, exposing over 10,000 patients to experimental procedures outside a transparent research framework. These findings highlight a systemic failure in surgical innovation governance and underscore an urgent need for a cultural shift towards mandatory, prospective oversight frameworks to ensure patient safety and credible evidence generation.
导航外科创新的未知领域:非标准代谢减肥手术程序的系统回顾。
背景:外科手术的创新常常超过可靠的评估。本研究以代谢减肥手术(MBS)这一高强度创新领域为例,评估手术实验过程的报告标准和伦理监督。方法按照PRISMA 2020指南进行系统评价。我们检索了2000年1月至2024年12月期间的PubMed/MEDLINE、Web of Science、Scopus、Cochrane Library和Embase,检索了与代谢减肥手术、外科创新和非标准肠旁路手术相关的术语。我们纳入了涉及重大肠道改变的非标准原发性MBS首次人体或早期临床系列的原始研究,排除了综述、社论、会议摘要、修正手术、纯限制性手术和基于设备的干预措施。两位审稿人独立筛选研究,提取发表时间、患者数量、随访、伦理批准和试验注册等数据,并使用纽卡斯尔-渥太华量表、乔安娜布里格斯研究所检查表和ROBINS-I工具评估偏倚风险。结果在纳入的57项研究(10754例患者)中,从首次人体手术到发表的中位时间为5年(IQR 3-8年)。初始队列中位数为39例(范围1-1074例)。47/57项研究(82%)报告了机构审查委员会或伦理批准,而前瞻性临床试验注册仅在6/57项研究(11%)中记录。方法学质量较低(纽卡斯尔-渥太华量表平均评分5.0/9),57项研究中有56项被判定为高偏倚风险。在57项研究中,只有15项(26%)报告了≥3年的结果,8项(14%)报告了≥5年的结果。本MBS案例研究揭示了延迟发表和普遍缺乏前瞻性试验注册,使10,000多名患者暴露在透明研究框架之外的实验程序中。这些发现强调了外科创新治理的系统性失败,并强调了迫切需要向强制性、前瞻性监督框架转变,以确保患者安全和可靠的证据生成。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
12.70
自引率
7.30%
发文量
1102
审稿时长
1.5 months
期刊介绍: The British Journal of Surgery (BJS), incorporating the European Journal of Surgery, stands as Europe's leading peer-reviewed surgical journal. It serves as an invaluable platform for presenting high-quality clinical and laboratory-based research across a wide range of surgical topics. In addition to providing a comprehensive coverage of traditional surgical practices, BJS also showcases emerging areas in the field, such as minimally invasive therapy and interventional radiology. While the journal appeals to general surgeons, it also holds relevance for specialty surgeons and professionals working in closely related fields. By presenting cutting-edge research and advancements, BJS aims to revolutionize the way surgical knowledge is shared and contribute to the ongoing progress of the surgical community.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书